Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.31 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21569657 | 0.79 | PRMT3 (0.37) | CYP2C9CYP2C19PRMT3CARM1PRMT6 | |
| SCHEMBL22162997 | 0.77 | PRMT3 (0.30) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL17655887 | 0.77 | DNM1 (0.39) | CYP2C9CYP2C19PRMT3CARM1PRMT6 | |
| SCHEMBL11359508 | 0.74 | DNM1 (0.46) | — | |
| SCHEMBL11366375 | 0.74 | DNM1 (0.46) | — | |
| SCHEMBL11363758 | 0.74 | DNM1 (0.46) | — | |
| SCHEMBL13315486 | 0.74 | TDP1 (0.35) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL14654569 | 0.73 | CACNA2D1 (0.39) | CYP2C19 | |
| SCHEMBL21386117 | 0.70 | CYP2C9 (0.38) | CYP2C9CYP2C19PRMT3CARM1PRMT6 | |
| SCHEMBL20079223 | 0.70 | CYP2C9 (0.38) | CYP2C9CYP2C19PRMT3CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180492-B2 | Anti-parasitic compounds and uses thereof | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20190002463-A1 | ANTI-PARASITIC COMPOUNDS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180492-B2 | Anti-parasitic compounds and uses thereof | MPO, GOT2, GOT1 | CYP2C9 510/4885CYP2C19 266/4885PRMT3 607/4885 |
| US-20190002463-A1 | ANTI-PARASITIC COMPOUNDS AND USES THEREOF | MPO, GOT2, GOT1 | CYP2C9 510/4885CYP2C19 266/4885PRMT3 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.